The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The MAR-Autism Test represents more than 20 years of research at the UC Davis MIND Institute by Judy Van de Water
The system is intended for some of the tiniest patients—premature infants weighing as little as two pounds
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
The state-of-the-art facility is expected to be commissioned over the next three years
The combination also outperformed chemotherapy on another important secondary endpoint
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
This is also an important milestone in our product strategy for our expansion into the larger Latin American market
Subscribe To Our Newsletter & Stay Updated
